Alphanate
FDA Label NDC 68516-4613

28 label sections · Submitted to the FDA by Grifols Usa, Llc · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Grifols Usa, Llc for the product Alphanate (NDC 68516-4613). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 dose, 2.2 reconstitution, 2.3 administration, 3 dosage forms and strengths, 4 contraindications, 5.1 hypersensitivity reactions, 5.2 neutralizing antibodies, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

1 Indications And Usage

ALPHANATE is indicated for:

  • Treatment  and prevention of bleeding episodes and perioperative management in adult and pediatric patients with Factor VIII (FVIII) deficiency due to hemophilia A.
  • Perioperative management in adult and pediatric patients with Type 1 and Type 2 von Willebrand Disease (VWD) in whom desmopressin (DDAVP) is either ineffective or contraindicated.
  • Perioperative management in minor surgery in adult and pediatric patients with Type 3 VWD.

2.1 Dose

For intravenous injection after reconstitution only

  • Each vial of ALPHANATE has the antihemophilic factor (AHF) potency (FVIII:C activity) expressed in International Units (IU) FVIII/vial on the label.  Additionally, ALPHANATE contains von Willebrand Factor:Ristocetin Cofactor (VWF:RCo), which is expressed in IU VWF:RCo/vial for the treatment of VWD.     
  • Treatment and Prevention of Bleeding Episodes and Excess Bleeding During and After Surgery in Patients with Hemophilia A

    • Dosage and duration of treatment depend on the severity of the FVIII deficiency, the location and extent of bleeding, presence of inhibitors, and the patient’s clinical condition. Careful control of replacement therapy is especially important in cases of major surgery or life-threatening bleeding episodes. 
    • Calculate dosing requirements and frequency of dosing on the basis of an expected initial response of 2% of normal FVIII:C increase per IU FVIII:C/kg body weight administered. Calculate the expected in vivo peak increase in FVIII level expressed as IU/dL (or % of normal) using the following formulas:
    • Dosage (international units) = body weight (kg) x desired FVIII rise (IU/dL or % normal) x 0.5 (IU/kg per IU/dL)

      or

      IU/dL (or % of normal) = [Total Dose (IU)/body weight (kg)] x 2

      • Titrate dose and frequency to the patient’s clinical response, including individualized needs, severity of the deficiency, severity of the hemorrhage, presence of inhibitors, and FVIII level desired.  Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses to ALPHANATE.
      • Table 1 provides dosage guidelines for the control and prevention of bleeding episodes in hemophilia A patients. Dosing should aim at maintaining a plasma factor VIII activity level at or above the plasma levels (in IU/dL or in % of normal) outlined in the table.
      • Table 1: Dosage Guidelines for Patients with Hemophilia A
        Type of Bleeding FVIII:C Level
        Required 
        (% of normal)
        Doses
        (IU/kg)
        Frequency of
        Doses
        (hours)
        Duration of Therapy
        (days)
        Minor
        Large bruises
        Significant cuts or scrapes
        Uncomplicated joint hemorrhage
        30% 15 12
        (twice daily)
        Until hemorrhage stops and healing has been achieved (1–2 days).
        Moderate
        Nose, mouth and gum bleeds
        Dental extractions
        Hematuria
        50% 25 12
        (twice daily)
        Until healing has been achieved (2–7 days, on average).
        Major
        Initial dose

        Joint hemorrhage
        Muscle hemorrhage
        Major trauma
        Hematuria
        Intracranial and
        intraperitoneal bleeding
        80% to 100%40 to 50
        12
        (twice daily)
        For at least 3–5 days


        Major
        Maintenance dose
        Joint hemorrhage
        Muscle hemorrhage
        Major trauma
        Hematuria
        Intracranial and
        intraperitoneal
        80% to 100%2512
        (twice daily)
        Until healing has been achieved for up to 10 days. 
        Intracranial hemorrhage may require prophylaxis therapy for up to 6 months.
        Surgery: Prior to
        surgery
        80% to 100%40 to 50Once-
        Surgery: After
        surgery
        60% to 100%30 to 50 12
        (twice daily)
        For the next 7–10 days, or until healing has been achieved.
        • Monitoring parameters:
          • Monitor plasma FVIII levels periodically to evaluate individual patient response to the dosage regimen.
          • If dosing studies have determined that a particular patient exhibits a lower/higher than expected response and shorter/longer half-life, adjust the dose and the frequency of dosing accordingly.
          • Failure to achieve the expected plasma FVIII:C level or to control bleeding after an appropriately calculated dosage may be indicative of the development of an inhibitor (an antibody to FVIII:C). Quantitate the inhibitor level by appropriate laboratory procedures and document its presence. Treatment with ALPHANATE in such cases must be individualized.
          • Treatment and Prevention of Excess Bleeding During and After Surgery or Other Invasive Procedures in Patients with von Willebrand Disease

            • The ratio of VWF:RCo to FVIII in ALPHANATE varies by lot, so with each new lot, check IU VWF:RCo/vial to ensure accurate dosing.
            • Dosage and duration of treatment depend on the severity of the VWF deficiency, the location and extent of bleeding, and the patient’s clinical condition. Careful control of replacement therapy is especially important in cases of major surgery or life-threatening bleeding episodes.
            • The median incremental in vivo recoveries of VWF:RCo and FVIII:C were 3.12 (IU/dL)/(IU/kg) [mean, 3.29 ± 1.46 (IU/dL)/(IU/kg); range: 1.28 to 5.73 (IU/dL)/(IU/kg)] for VWF:RCo and 1.95 (IU/dL)/(IU/kg) [mean, 2.13 ± 0.58 (IU/dL)/(IU/kg); range: 1.33 to 3.32 (IU/dL)/(IU/kg)] for FVIII:C.
            • Table 2 provides dosing guidelines for pediatric and adult patients with VWD with minor bleeding or undergoing minor surgery.
            • Table 2: Dosage Guidelines for Patients with von Willebrand Disease for Minor Surgery or Minor Bleeding
              ParameterVWF:RCoTarget FVIII:C
              Activity Levels
              Pre-operative/pre-procedure
              dose: adult
              60 IU VWF:RCo/kg body weight40 IU/dL to 50 IU/dL
              Maintenance dose: adult40 IU to 60 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for 1 to 3 days40 IU/dL to 50 IU/dL
              Pre-operative/pre-procedure
              dose: pediatric
              75 IU VWF:RCo/kg body weight40 IU/dL to 50 IU/dL
              Maintenance dose: pediatric50 IU to 75 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for 1 to 3 days40 IU/dL to 50 IU/dL
              Therapeutic Goal (Trough):>50 IU/dL>50 IU/dL
              Safety Monitoring:Peak and trough at least once dailyPeak and trough at least once daily
              Safety Parameter:Should not exceed 150 IU/dLShould not exceed
              150 IU/dL
              • Table 3 provides dosing guidelines for pediatric and adult patients with VWD with major bleeding or major surgery.
              • Table 3: Dosage Guidelines for Patients with von Willebrand Disease for Major Surgery or Major Bleeding (Except Type 3 Patients Undergoing Major Surgery)
                ParameterVWF:RCoTarget FVIII:C
                Activity Levels
                Pre-operative/pre-procedure
                dose: adult
                60 IU VWF:RCo/kg body weight 100 IU/dL
                Maintenance dose: adult40 IU to 60 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for at least 3 to 7 days 100 IU/dL
                Pre-operative/pre-procedure
                dose: pediatric
                75 IU VWF:RCo/kg body weight 100 IU/dL
                Maintenance dose: pediatric50 IU to 75 IU VWF:RCo/kg body weight at 8 to 12 hour intervals as clinically needed for at least 3 to 7 days 100 IU/dL
                Therapeutic Goal (Trough): >50 IU/dL >50 IU/dL
                Safety Monitoring: Peak and trough at least daily Peak and trough at least daily
                Safety Parameter: Should not exceed 150 IU/dL Should not exceed 150 IU/dL

2.2 Reconstitution

  • Always use aseptic technique.
  • Ensure that concentrate (ALPHANATE) and diluent (Sterile Water for Injection, USP) are at room temperature (but not above 37 ˚C) before reconstitution.
  • Remove the plastic flip off cap from the diluent vial.
  • Gently swab the exposed stopper surface with a cleansing agent such as alcohol trying to avoid leaving any excess cleansing agent on the stopper.
  • Open the Mix2Vial® package by peeling away the lid (Figure 1).  Leave the Mix2Vial in the clear outer packaging.
  • Place the diluent vial upright on an even surface and hold the vial tight and pick up the Mix2Vial in its clear outer packaging.  Holding the diluent vial securely, push the blue end of the Mix2Vial vertically down through the diluent vial stopper (Figure 2).
  • While holding onto the diluent vial, carefully remove the clear outer packaging from the Mix2Vial set, ensuring the Mix2Vial remains attached to the diluent vial (Figure 3).
  • Place the product vial upright on an even surface, invert the diluent vial with the Mix2Vial attached.
  • While holding the product vial securely on a flat surface, push the clear end of the Mix2Vial set vertically down through the product vial stopper (Figure 4).  The diluent will automatically transfer out of its vial into the product vial.

    NOTE: If the Mix2Vial is connected at an angle, the vacuum may be released from the product vial and the diluent will not transfer into the product vial.

  • With the diluent and product vials still attached to the Mix2Vial, gently swirl the product vial to ensure the product is fully dissolved (Figure 5).  Reconstitution requires less than 5 minutes. Do not shake the vial.
  • Disconnect the Mix2Vial into two separate pieces (Figure 6) by holding each vial adapter and twisting counterclockwise.  After separating, discard the diluent vial with the blue end of the Mix2Vial.
  • Draw air into an empty, sterile syringe.  Keeping the product vial upright with the clear end of the Mix2Vial attached, screw the disposable syringe onto the luer lock portion of the Mix2Vial device by pressing and twisting clockwise.  Inject air into the product vial.
  • While keeping the syringe plunger depressed, invert the system upside down and draw the reconstituted product into the syringe by pulling the plunger back slowly (Figure 7).
  • When the reconstituted product has been transferred into the syringe, firmly hold the barrel of the syringe and the clear vial adapter (keeping the syringe plunger facing down) and unscrew the syringe from the Mix2Vial (Figure 8).  Hold the syringe upright and push the plunger until no air is left in the syringe.  Attach the syringe to a venipuncture set.

    NOTE: If the same patient is to receive more than one vial of concentrate, the contents of two vials may be drawn into the same syringe through a separate unused Mix2Vial set before attaching to the venipuncture set.

  • When reconstitution procedure is strictly followed, a few small particles may occasionally remain.  The Mix2Vial set will remove particles and the labeled potency will not be reduced.
  • Discard all reconstitution equipment after use into the appropriate safety container. Do not reuse.
  • Use the prepared drug as soon as possible within 3 hours after reconstitution.                         
  • Figures 1-8 (Alp03 0009 01)

    Figures 1-8 (Alp03 0009 01)

2.3 Administration

For intravenous use after reconstitution only

  • Inspect parenteral drug products visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
  • Do not refrigerate after reconstitution.  Store reconstituted ALPHANATE at room temperature (not to exceed 30 °C) prior to administration but administer intravenously within three hours.
  • Use plastic disposable syringes.
  • Do not administer ALPHANATE at a rate exceeding 10 mL/minute.
  • Discard any unused contents into the appropriate safety container.

3 Dosage Forms And Strengths

ALPHANATE is available as a lyophilized powder for intravenous injection after reconstitution. It is available in the following potencies:

250 IU FVIII/5 mL single-dose vial
500 IU FVIII/5 mL single-dose vial
1000 IU FVIII/10 mL single-dose vial
1500 IU FVIII/10 mL single-dose vial
2000 IU FVIII/10 mL single-dose vial

4 Contraindications

None.

5.1 Hypersensitivity Reactions

Severe hypersensitivity reactions including anaphylaxis have occurred during or after ALPHANATE administration.  Early signs of allergic reactions, which can progress to anaphylaxis, may include angioedema, chest tightness, hypotension, rash, nausea, vomiting, paresthesia, restlessness, wheezing and dyspnea. Discontinue use of ALPHANATE if hypersensitivity symptoms occur and initiate appropriate treatment.

5.2 Neutralizing Antibodies

Neutralizing antibodies (inhibitors) to von Willebrand Factor and Factor VIII have occurred following administration of ALPHANATE.  Monitor patients for the development of neutralizing antibodies by appropriate clinical observations and laboratory tests. If expected plasma FVIII/VWF activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an appropriate assay that measures FVIII/VWF inhibitor concentration.

5.3 Thromboembolic Events

Thromboembolic events have been reported with ALPHANATE administration [see Adverse Reactions (6)]. Risk factors for thromboembolic events include patients with von Willebrand Disease, elderly age, previous thrombosis, metabolic syndrome, cancer, surgery, oral contraceptive and hormone therapy, diabetes, hypertension, hyperlipidemia, smoking, and pregnancy. Monitor plasma levels of VWF:RCo and FVIII activities to avoid sustained excessive VWF and FVIII activity levels (greater than 150 IU/dL), which may increase the risk of thrombotic events, during continued treatment with ALPHANATE. Consider antithrombotic measures in patients with at risk for thrombosis. [see Monitoring: Laboratory Tests (5.7)].

5.4 Intravascular Hemolysis

Intravascular hemolysis may occur following treatment with ALPHANATE as it contains blood group specific isoagglutinins. Risk factors for hemolysis include large and/or frequent doses of ALPHANATE in patients with blood groups A, B, or AB. Monitor patients for clinical signs and symptoms of hemolysis. If hemolysis occurs, pause infusion if ongoing and manage according to clinical practice.

5.5 Vasomotor Reactions

Do not administer ALPHANATE at a rate exceeding 10 mL/minute. Rapid administration of ALPHANATE may result in vasomotor reactions.

5.6 Transmissible Infectious Agents

Because ALPHANATE is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob Disease (vCJD) agent and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain virus infections, and by inactivating and/or removing certain viruses during manufacturing. [see Description (11)].

5.7 Monitoring: Laboratory Tests

Monitor for development of FVIII and VWF inhibitors. Perform appropriate assays to determine if FVIII and/or VWF inhibitor(s) are present if bleeding is not controlled with expected dose of ALPHANATE.

Monitor plasma levels of VWF:RCo and FVIII activities to avoid sustained excessive VWF and FVIII activity levels (greater than 150 IU/dL), which may increase the risk of thrombotic events, particularly in patients with known risk factors.

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.

Other

Hemophilia A

In a prospective clinical study with ALPHANATE, 23 patients were exposed to 1217 infusions (median=42, range 2 to 160).  The total number of exposure days was 1133, and the total number of months on study across all patients was 234 (19.5 patient years). 

von Willebrand Disease (VWD)

In the prospective clinical study of ALPHANATE[using both ALPHANATE Solvent Detergent (A-SD, a previous generation product) and ALPHANATE Solvent Detergent/Heat Treated (A-SD/HT, the current generation product)] in patients with VWD, adverse reactions occurred in 5 of 36 patients (13.9%) treated with ALPHANATE (A-SD/HT).

Sixty-one total adverse reactions were reported in 204 infusions.  The majority of adverse reactions were rated as mild (55 of 61 [90.2%]) and six (9.8%) were rated as moderate.

Overall, the proportion of infusions associated with adverse reactions was 14 of 204 infusions (6.9%). The most common adverse reactions reported (> 1% of infusions) were pruritus, headache, backpain, paresthesia, respiratory distress, facial edema, pain, rash, and chills.

One incident of pulmonary embolism was reported that was considered to have a possible relationship to the product.  This patient received a dose of 60 IU VWF:RCo/kg body weight and the FVIII:C level achieved was 290%.

In the retrospective study conducted to determine the efficacy and safety of ALPHANATE (A-SD/HT) in a surgical or invasive procedure setting as perioperative prophylaxis against excessive bleeding [see Clinical Studies (14)], 3 out of 39 patients (7.7%) experienced 6 adverse reactions. Four were considered mild and 2 were considered moderate adverse reactions. The adverse reactions were pruritus, paresthesia (2 events) and hemorrhage, (all considered mild), and one event each of moderate hematocrit decrease and orthostatic hypotension.

One adverse reaction (pain) related to the treatment with heat-treated ALPHANATE (A-SD/HT) was reported in the four pediatric patients with VWD during the course of the prospective study and in none of the five pediatric patients in the retrospective clinical study.

Virus Reduction Capacity

The results of virus validation studies performed to determine virus reduction factors associated with several steps in the manufacturing process of ALPHANATE are summarized in Table 5.

In vitro inactivation studies to evaluate the solvent detergent treatment (0.3% TNBP and 1% polysorbate 80) step in the manufacture of ALPHANATE were conducted to assess the capability of the step to inactivate enveloped viruses, such as Human Immunodeficiency viruses (HIV), as well as marker viruses such as Sindbis virus (SIN, a model for Hepatitis C virus (HCV)), Vesicular Stomatitis virus (VSV, a model for large, enveloped RNA virus), Bovine Herpes virus (BHV, a model for Hepatitis B virus) and Bovine Viral Diarrhea virus (BVD, a model for HCV).  In vitro inactivation studies to evaluate the dry heat treatment (80 °C, 72 hours) step in the manufacture of ALPHANATE were conducted to assess the capability of the step to inactivate both enveloped and non-enveloped viruses, such as Hepatitis A virus (HAV), human Poliovirus Sabin type 2 (POL, a model for HAV), Canine Parvovirus (CPV, a model for Parvovirus B19), BHV and BVD.  Other steps in the manufacturing process of ALPHANATE (precipitation with 3.5% polyethylene glycol (PEG), heparin affinity chromatography and lyophilization) were also evaluated for virus elimination capability using several enveloped and non-enveloped viruses as shown in Table 5.

Table 5: Virus Log10 Reduction
Virus
(Model Virus for)
3.5% PEG
Precipitation
Solvent-
Detergent
Column
Chromatography
LyophilizationDry Heat Cycle
(80 °C, 72 hr)
Total Log10
Reduction
BHV

Abbreviations used: BHV = Bovine Herpes Virus (model for HBV); BVD = Bovine Viral Diarrhea Virus (model for HCV); POL = Human Poliovirus Sabin type 2 (model for HAV); CPV = Canine Parvovirus (model for Parvovirus B19); VSV = Vesicular Stomatitis Virus (model for large, enveloped RNA virus); SIN = Sindbis Virus (model for HCV); HIV-1 and HIV-2 = Human Immunodeficiency Viruses; HAV = hepatitis A virus


(HBV)
< 1.0≥ 8.07.61.32.1≥ 19.0
BVD
(HCV)
< 1.0≥ 4.5< 1.0< 1.0≥ 4.9≥ 9.4
POL
(HAV)
3.3–< 1.03.4≥ 2.5≥ 9.2
CPV
(B19)
1.2–< 1.0< 1.04.15.3
VSV–≥ 4.1–––≥ 4.1
SIN
(HCV)
–≥ 4.7–––≥ 4.7
HIV–1< 1.0≥ 11.1≥ 2.0––≥ 13.1
HIV–2–≥ 6.1–––≥ 6.1
HAV–––2.1≥ 5.8≥ 7.9

Additionally, the manufacturing process was investigated for its capacity to decrease infectivity of an experimental agent of transmissible spongiform encephalopathy (TSE), considered as a model for the vCJD and CJD agents.

Several of the individual production steps in ALPHANATE manufacturing process have been shown to decrease TSE infectivity of an experimental model agent. TSE reduction steps include: 3.5% polyethylene glycol precipitation (3.23 log10), affinity chromatography (3.50 log10) and saline precipitation (1.36 log10). These studies provide reasonable assurance that low levels of CJD/vCJD agent infectivity, if present in the starting material, would be removed.

Pharmacokinetics in Hemophilia A

Following the administration of ALPHANATE during clinical trials, the mean in vivo half-life of FVIII observed in 12 adult patients with severe hemophilia A was 17.9 ± 9.6 hours.  In this same study, the in vivo recovery was 96.7 ± 14.5% at 10 minutes post-infusion.  Recovery at 10 minutes post-infusion was 2.4 ± 0.4 IU FVIII rise/dL plasma per IU FVIII infused/kg body weight.

Pharmacokinetics in von Willebrand Disease (VWD)

A pharmacokinetic crossover study was conducted in 14 non-bleeding patients with VWD (1 type 1, 2 type 2A, and 11 type 3) comparing the pharmacokinetics of ALPHANATE (A-SD/HT) and an earlier formulation, ALPHANATE (A-SD).  Patients received, in random order at least seven days apart, a single intravenous dose of each product, 60 IU VWF:RCo/kg (75 IU VWF:RCo/kg in patients younger than 18 years of age).  Pharmacokinetic parameters were similar for the two products and indicated that they were biochemically equivalent.  Pharmacokinetic analysis of ALPHANATE (A-SD/HT) in the 14 patients revealed the following results: the median plasma levels (% normal) of VWF:RCo rose from 10 IU/dL (range: 10 to 27 IU/dL) at baseline to 206 IU/dL (range: 87 to 440 IU/dL) 15 minutes post-infusion; median plasma levels of FVIII:C rose from 5 IU/dL (range: 2 to 114 IU/dL) to 206 IU/dL (range: 110 to 421 IU/dL).   The median bleeding time (BT) prior to infusion was 30 minutes (mean, 28.8 ± 4.41 minutes; range: 13.5 to 30 minutes), which shortened to 10.38 minutes (mean, 10.4 ± 3.2 minutes; range: 6 to 16 minutes) 1 hour post-infusion.  

Following infusion of ALPHANATE (A-SD/HT), the median half-lives for VWF:RCo, FVIII:C and VWF:Ag were 6.91 hours (range: 3.8 to 16.22 hours), 20.92 hours (range: 7.19 to 32.2 hours), and 12.8 hours (range: 10.34 to 17.45 hours), respectively.  The median incremental in vivo recoveries of VWF:RCo and FVIII:C were 3.12 (IU/dL)/(IU/kg) [range: 1.28 to 5.73 (IU/dL)/(IU/kg)] for VWF:RCo and 1.95 (IU/dL)/(IU/kg) [range: 1.33 to 3.32 (IU/dL)/(IU/kg)] for FVIII:C.

The pharmacokinetic data in VWD are summarized in Table 6.

Table 6: Pharmacokinetic Data in von Willebrand Disease
Parameter
Plasma VWF:RCo
(Mean ± SD)
Plasma FVIII:C
(Mean ± SD)
Plasma VWF:Ag
(Mean ± SD)
Number of patients141414
Mean plasma levels (IU/dL):
Baseline
11.86 ± 4.9721.00 ± 33.83–
Mean plasma levels (IU/dL):
15 minutes post infusion
215.50 ± 101.70215.29 ± 94.26–
T½ (Half-life in hours)7.67 ± 3.3221.58 ± 7.7913.06 ± 2.20
Incremental in vivo recovery
in (IU/dL)/(IU/kg)
3.29 ± 1.462.13 ± 0.58–

Following infusion of both ALPHANATE (A-SD) and ALPHANATE (A-SD/HT), an increase in the size of VWF multimers was seen and persisted for at least 24 hours.  The shortening of the BT was transient, lasting less than 6 hours following treatment and did not correlate with the presence of large and intermediate size VWF multimers.

In a prospective, multi-center clinical study, 37 patients with VWD (6 Type 1, 19 Type 2, 12 Type 3) underwent 59 surgical procedures for which ALPHANATE (A-SD) or ALPHANATE (A-SD/HT) was administered [21 patients received ALPHANATE (A-SD), 18 received ALPHANATE (A-SD/HT), and 2 received both products] for bleeding prophylaxis (see Table 7).  An initial pre-operative infusion of 60 IU VWF:RCo/kg (75 IU VWF:RCo/kg for patients less than 18 years of age), was administered one hour before surgery.  A blood sample was obtained 15 minutes after the initial infusion for the determination of the plasma FVIII:C level.  The level had to equal or exceed 100% of normal for an operation to proceed.  No cryoprecipitate or alternative FVIII product was administered during these surgical procedures.  Platelets were required in two patients. The protocol permitted intra-operative infusions of ALPHANATE (A-SD) and ALPHANATE (A-SD/HT) at 60 IU VWF:RCo/kg (75 IU VWF:RCo/kg for patients less than 18 years of age) to be administered as required according to the judgment of the investigator.

Table 7: Number of and Types of Surgical Procedures with ALPHANATE (A-SD) or ALPHANATE (A-SD/HT) Treatment
Type of Surgical ProcedureA-SD
(N = 21 patients)
A-SD/HT
(N = 18 patients)
Total
(N=37
 patients)
Dental14620
Dermatologic112
Gastrointestinal448
Gastrointestinal (diagnostic)606
Genitourinary022
Gynecologic213
Head and neck112
Orthopedic437
Vascular369
Total number of procedures352459

Two patients received both preparations; the total number of patients is therefore less than the sum of the columns.

Post-operative infusions at doses of 40 to 60 IU VWF:RCo/kg (50 to 75 IU VWF:RCo/kg for pediatric patients) were administered at 8 to 12-hour intervals until healing had occurred.  For maintenance of secondary hemostasis (after primary hemostasis was achieved), the dose was reduced after the third post-operative day [see Dosage and Administration (2.1)].

Overall, in the surgical procedures using either product, the BT at 30 minutes post-infusion was fully corrected in 18 (32.7%) cases, partially corrected in 24 (43.6%) cases, not corrected in 12 (21.8%) cases, and was not done in one case (1.8%).  Overall, the mean blood loss was lower than predicted prospectively. 

Surgical infusion summary data are included in Table 8.

Table 8: Prophylaxis with ALPHANATE (A-SD) and/or ALPHANATE (A-SD/HT) in Surgery
ParameterA-SDA-SD/HTTotal
Number of patients 211837

Two patients received both products.

Number of surgical procedures352459
Median number of infusions per surgical procedure (range)3 (1-13)4 (1 – 18)4 (1-18)
Median dosage IU VWF:RCo/kg, Infusion #1 (range)59.8 (19.8-75.1)59.9 (40.6 – 75.0)59.9 (19.8-75.1)
Median dosage IU VWF:RCo/kg, Infusion ≥ #2 combined  (range)40.0 (4.5-75.1)40.0 (10.0 – 63.1)40.0 (4.5-75.1)

Additionally, surgical procedures using ALPHANATE SD/HT only were categorized as major, minor or invasive procedures according to definitions used in the study.  The outcome of each surgery was evaluated according to a clinical rating scale (excellent, good, poor or none) and was considered successful if the outcome was excellent or good. 

Study results also were evaluated independently by two referees with clinical experience in this field in the same way (surgery categorization and outcome of each surgery according to a clinical rating scale). There was a high level of agreement between the referee evaluations and the analyzed outcome data, with a decrease of only a single success in achieving hemostasis (21/24 [referees evaluation] vs. 22/24 [investigators evaluation]).

Retrospective Study

A retrospective, multi-center study was performed to assess the efficacy of ALPHANATE (A-SD/HT) as replacement therapy in preventing excessive bleeding in patients with congenital VWD undergoing surgical or invasive procedures, for whom DDAVP was ineffective or inadequate.  A total of 61 surgeries/procedures in 39 patients were evaluated.

Of the 39 patients, 18 had Type 1 VWD (46.2%); 12 patients (30.8%) had Type 2 VWD, and 9 patients (23.1%) had Type 3 VWD. Median age was 40 years; approximately one-half of the patients were male.

The primary efficacy variable was the overall treatment outcome for each surgical or invasive procedure, as rated by the investigator using a 4-point verbal rating scale (VRS): “excellent,” “good,” “poor,” or “none (no indication of efficacy).”  The categorization of the replacement treatment outcome was based upon the investigator’s clinical experience and defined in Table 9.

Table 9: Rating Scale and Clinical Efficacy of ALPHANATE Therapy
RatingHemostasis

The efficacy assessment period included the entire perioperative period. 

Dosing
Excellent Hemostasis not different from that expected for patients without known bleeding disorders. No upward dosage adjustment for ALPHANATE replacement therapy.
Good Hemostasis slightly inferior from that expected for patients without known bleeding disorders but judged as not clinically relevant. Minor upward dosage adjustment for ALPHANATE replacement therapy.
Poor Less hemostasis than expected for patients without known bleeding disorders attributed to VWD despite ALPHANATE replacement therapy. Relevant upward dosage adjustment for ALPHANATE replacement therapy. No need for alternative therapy. 
None Severe bleeding attributed to VWD despite ALPHANATE replacement therapy. Relevant upward dosage adjustment for ALPHANATE replacement therapy and/or need for alternative unexpected therapy.

In addition, an independent referee committee was convened to evaluate the efficacy outcomes.  More than 90% of the surgical outcomes received an investigator and referee’s overall and daily rating of “effective” (“excellent” or “good”) in achieving hemostasis/preventing bleeding.

The majority of ratings were considered “excellent” (≥ 81.3% in each VWD type).  Nine Type 3 patients underwent 1 major and 15 minor procedures.  Two procedures (1 major and 1 minor) in 1 patient with Type 3 VWD received an overall efficacy rating of “none,” and one minor procedure in a patient with Type 2 VWD received an overall efficacy rating of “poor.”

6.2 Postmarketing Experience

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse reactions have been identified during postmarketing use of ALPHANATE:

General disorders and administration site conditions: fever, fatigue, and infusion site pain

Gastrointestinal disorders: nausea

Musculoskeletal and connective tissue disorders: joint pain

Immune system disorders: allergic/hypersensitivity reactions

8.1 Pregnancy

Risk Summary

There are no data on the use of ALPHANATE in pregnant women to inform on drug-associated risk. Animal reproduction studies have not been conducted with ALPHANATE.  It is also not known whether ALPHANATE can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity.  Use ALPHANATE in pregnant women only if clearly needed.

The estimated background risk of major birth defects and miscarriage in the U.S. general population in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.

8.2 Lactation

Risk Summary

There is no information regarding the presence of ALPHANATE in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ALPHANATE and any potential adverse effects on the breast-fed infant from ALPHANATE or from the underlying maternal condition.

8.4 Pediatric Use

Hemophilia A

The safety and efficacy of ALPHANATE have been established in pediatric patients with Hemophilia A. There were 21 patients aged 7 to 16 years enrolled in a single clinical trial who received ALPHANATE weekly for prophylaxis or anytime for suspected bleeds.  They were successfully treated for 1499 bleeding episodes or as prophylaxis to prevent them (e.g. pain in the joint). The median number of units needed to treat the bleeds was 420 IU, with a range of 210 IU to 1620 IU. 

Von Willebrand Disease

The safety and efficacy of ALPHANATE have been established in pediatric patients with Von Willebrand Disease.  The hemostatic efficacy of ALPHANATE has been studied in 20 pediatric patients (ages 7 to 18 years) with VWD.  Based on the data from a subset of these patients, age had no effect on the pharmacokinetics of VWF:RCo. 

8.5 Geriatric Use

The safety and effectiveness of ALPHANATE have not been studied in geriatric patients ≥ 65 years of age.   

11 Description

ALPHANATE (antihemophilic factor/von Willebrand factor complex [human]) is a sterile, lyophilized concentrate of FVIII (AHF) and von Willebrand Factor (VWF).

ALPHANATE is prepared from pooled human plasma by cryoprecipitation of FVIII, fractional solubilization, and further purification employing heparin-coupled, cross-linked agarose which has an affinity to the heparin binding domain of VWF/FVIII:C complex.  The product is treated with a mixture of tri-n-butyl phosphate (TNBP) and polysorbate 80 to inactivate enveloped viruses.  The product is also subjected to an 80 °C heat treatment step for 72 hours to inactivate enveloped and non-enveloped viruses.  However, no procedure has been shown to be totally effective in removing viral infectivity from coagulation factor products.

ALPHANATE is labeled with the antihemophilic factor potency (FVIII:C activity) in International Units (IU) FVIII/vial and with VWF:RCo activity expressed in IU VWF:RCo/vial. The activities are referenced to their respective international standards established by the World Health Organization. One IU of FVIII or one IU of VWF:RCo is approximately equal to the amount of FVIII or VWF:RCo activity in 1 mL of freshly-pooled human plasma.

ALPHANATE contains human albumin as a stabilizer, resulting in a final container concentrate with a specific activity of at least 5 FVIII:C IU/mg total protein. ALPHANATE contains no preservatives.

The composition of ALPHANATE after reconstitution is provided in Table 4:

Table 4: Composition (per Vial) of ALPHANATE Following Reconstitution with Sterile Water for Injection, U.S.P.
IngredientUnits250 IU
vial
500 IU
vial
1000 IU 
vial
1500 IU
vial
2000 IU
vial
Factor VIIIIU250500100015002000
von Willebrand Factor IU per
1000 IU
FVIII
> 400 > 400 > 400 > 400> 400
Albumin (Human) mg 25 25 50 50 50
Arginine mg 90 90 175 175 175
Histidine mg 20 20 40 40 40
Water for Injection

Supplied in a separate diluent vial

mL 5 5 10 10 10

12.1 Mechanism Of Action

ALPHANATE contains antihemophilic factor (FVIII) and von Willebrand factor (VWF), constituents of normal plasma.  FVIII is an essential cofactor in activation of factor X leading to formation of thrombin and fibrin.  VWF promotes platelet aggregation and platelet adhesion on damaged vascular endothelium; it also serves as a stabilizing carrier protein for the procoagulant protein FVIII.

After administration, ALPHANATE temporarily replaces the missing coagulation FVIII and VWF needed for effective hemostasis.

12.2 Pharmacodynamics

There have been no specific pharmacodynamic studies on ALPHANATE.

14 Clinical Studies

Von Willebrand Disease

Prospective Study

16 How Supplied/Storage And Handling

How Supplied

ALPHANATE is supplied in sterile, lyophilized form in a single-dose vial with a vial of diluent (Sterile Water for Injection, USP) and a Mix2Vial filter transfer set.  IU activity of FVIII and VWF:RCo are stated on the carton and label of each vial.

ALPHANATE is available in the following potencies and color coded based upon assay on the carton and label as follows:

PotencyNDCAssay Color Code
250 IU FVIII/5 mL single-dose vial68516-4616-1250 IU FVIII Range – gray box
500 IU FVIII/5 mL single-dose vial68516-4617-1500 IU FVIII Range - green box
1000 IU FVIII/10 mL single-dose vial68516-4618-21000 IU FVIII Range – blue box
1500 IU FVIII/10 mL single-dose vial68516-4619-21500 IU FVIII Range – orange box
2000 IU FVIII/10 mL single-dose vial68516-4620-22000 IU FVIII Range - magenta box

Storage And Handling

Storage and Handling

ALPHANATE is stable for three years, up to the expiration date printed on its label, provided that the storage temperature does not exceed 25 °C (77 °F). Do not freeze. 

17 Patient Counseling Information

Advise the patient and/or caregiver:

  • To contact their healthcare provider or go to the emergency department right away if a hypersensitivity reaction occurs. Early signs of hypersensitivity reactions may include rash, hives, itching, facial swelling, tightness of the chest, and wheezing [see Warnings and Precautions (5.1)].
  • To contact their healthcare provider or treatment center for further treatment and/or assessment if they experience a lack of clinical response to factor VIII replacement therapy, as this may be a manifestation of an inhibitor [see Warnings and Precautions (5.2)].
  • To contact their healthcare provider or go to the emergency department right away if a thromboembolic event should occur [see Warnings and Precautions (5.3)].
  • That despite stringent procedures designed to reduce risk, the risk of transmitting infectious agents cannot be totally eliminated. Advise patients, especially pregnant women and immunocompromised individuals, to report any signs and symptoms of fever, rash, joint pain, or sore throat, to their healthcare provider immediately [see Warnings and Precautions (5.6)].
  • Manufactured by:
    Grifols Biologicals LLC
    5555 Valley Boulevard
    Los Angeles, CA 90032, U.S.A.
    U.S. License No. 1694

    3070770

Package Label.Principal Display Panel

Principal Display Panel – 250 IU Vial Label

NDC 68516-4605-1     250 IU FVIII Range

Antihemophilic Factor/
von Willebrand Factor
Complex (Human)
Alphanate®     5 mL

Solvent Detergent / Heat Treated

Storage: Store at temperatures
not exceeding 25 °C (77 °F).
Rx only. Single dose container for
intravenous administration only. 

GRIFOLS U.S. License No. 1694

Instructions: Reconstitute
with 5 mL of Sterile Water
for Injection, USP. Administer
promptly after reconstitution
and do not refrigerate. Discard
unused contents. For information
on dosage and directions for
administration, see accompanying
pamphlet. Contains no
preservatives. The patient and
physician should discuss the risks
and benefits of this product.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, U.S.A.

Lot

EXP

IU FVIII/Vial

IU VWF:RCo/Vial           3063712

Lot

IU FVIII/Vial

IU VWF:RCo/Vial

Alphanate® 5 mL NDC 68516-4605-1

Vial Label 250iu 5ml (250iulabel)

Vial Label 250iu 5ml (250iulabel)

Principal Display Panel – 250 IU Carton Label

NDC 68516-4616-1      250 IU FVIII Range

Antihemophilic Factor/von Willebrand
Factor Complex (Human)
Alphanate®

Solvent Detergent / Heat Treated

Rx only
  
For Intravenous Administration                5 mL

GRIFOLS


Contents: One vial Antihemophilic Factor/von Willebrand
Factor Complex (Human), Alphanate®, one vial
5 mL Sterile Water for Injection, USP, one
Mix2Vial® filter transfer set, and directions for use.

Composition:
Factor VIII, von Willebrand Factor, Arginine, Albumin
and Histidine.
Contains no preservatives.
Administer within three hours of reconstitution.
Discard unused content.

GRIFOLS

Warning:
This product is prepared from large pools of
human plasma. Human blood and its components
may transmit infectious agents. See package
insert, WARNINGS AND PRECAUTIONS.

Instructions: The patient and physician should
discuss the risks and benefits of this product.
For information on dosage and directions for
administration, see enclosed package insert.

Storage: Store at temperatures not exceeding
25 °C (77 °F). Do not freeze.
Single dose container for intravenous
administration only.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, USA
U.S. License No. 1694

GRIFOLS

3070771

GTIN 00368516461617
LOT XXXXXXXXXX
EXP DDMMMYYYY
SN XXXXXXXXXX XXXXXX
IU FVIII/Vial XXXX
IU VWF: RCo/Vial XXXX 

Carton Label 250iu 5ml (Cartonlabel250iu)

Carton Label 250iu 5ml (Cartonlabel250iu)

Principal Display Panel – 500 IU Vial Label


NDC 68516-4606-1   500 IU FVIII Range

Antihemophilic Factor/
von Willebrand Factor
Complex (Human)
Alphanate®      5 mL

Solvent Detergent / Heat Treated
Storage: Store at temperatures
not exceeding 25 °C (77 °F).
Rx only. Single dose container for
intravenous administration only. 

GRIFOLS  U.S. License No. 1694

Instructions: Reconstitute
with 5 mL of Sterile Water
for Injection, USP. Administer
promptly after reconstitution
and do not refrigerate. Discard
unused contents. For information
on dosage and directions for
administration, see accompanying
pamphlet. Contains no
preservatives. The patient and
physician should discuss the risks
and benefits of this product.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, U.S.A.

Lot

EXP

IU FVIII/Vial

IU VWF:RCo/Vial           3063710

Lot

IU FVIII/Vial

IU VWF:RCo/Vial

Alphanate® 5 mL  NDC 68516-4606-1

Vial Label 500iu 5ml (500iulabel)

Vial Label 500iu 5ml (500iulabel)

Principal Display Panel – 500 IU Carton Label 

NDC 68516-4617-1              500 IU FVIII Range

Antihemophilic Factor/von Willebrand
Factor Complex (Human)
Alphanate®

Solvent Detergent / Heat Treated

Rx only

For Intravenous Administration                 5 mL

GRIFOLS

Contents: 
One vial Antihemophilic Factor/von Willebrand
Factor Complex (Human), Alphanate®, one vial
5 mL Sterile Water for Injection, USP, one
Mix2Vial® filter transfer set, and directions for use.

Composition:
Factor VIII, von Willebrand Factor, Arginine, Albumin
and Histidine.
Contains no preservatives.
Administer within three hours of reconstitution.
Discard unused contents.

GRIFOLS

Warning:
This product is prepared from large pools of
human plasma. Human blood and its components
may transmit infectious agents. See package
insert, WARNINGS AND PRECAUTIONS.

Instructions: The patient and physician should
discuss the risks and benefits of this product.
For information on dosage and directions for
administration, see enclosed package insert.

Storage: Store at temperatures not exceeding
25 °C (77 °F). Do not freeze.
Single dose container for intravenous
administration only.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, USA
U.S. License No. 1694

GRIFOLS

3070772

GTIN 00368516461716
LOT XXXXXXXXXX
EXP DDMMMYYYY
SN XXXXXXXXXX XXXXXX
IU FVIII/Vial XXXX
IU VWF: RCo/Vial XXXX

Carton Label 500iu 5ml (Cartonlabel500iu)

Carton Label 500iu 5ml (Cartonlabel500iu)

Principal Display Panel – 1000 IU Vial Label

NDC 68516-4607-2       1000 IU FVIII Range

Antihemophilic Factor/
von Willebrand Factor
Complex (Human)
Alphanate®       10 mL

Solvent Detergent / Heat Treated
Storage: Store at temperatures
not exceeding 25 °C (77 °F).
Rx only. Single dose container for
intravenous administration only. 

GRIFOLS  U.S. License No. 1694

Instructions: Reconstitute
with 10 mL of Sterile Water
for Injection, USP. Administer
promptly after reconstitution
and do not refrigerate. Discard
unused contents. For information
on dosage and directions for
administration, see accompanying
pamphlet. Contains no
preservatives. The patient and
physician should discuss the risks
and benefits of this product.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, U.S.A.

Lot

EXP

IU FVIII/Vial

IU VWF:RCo/Vial           3063708

Lot

IU FVIII/Vial

IU VWF:RCo/Vial

Alphanate®   10 mL  NDC 68516-4607-2

Vial Label 1000iu 10ml (1000iulabel)

Vial Label 1000iu 10ml (1000iulabel)

Principal Display Panel – 1000 IU Carton Label

NDC 68516-4618-2            1000 IU FVIII Range

Antihemophilic Factor/von Willebrand
Factor Complex (Human)
Alphanate®

Solvent Detergent / Heat Treated

Rx only

For Intravenous Administration                 10 mL

GRIFOLS

Contents: 
One vial Antihemophilic Factor/von Willebrand
Factor Complex (Human), Alphanate®, one vial
10 mL Sterile Water for Injection, USP, one
Mix2Vial® filter transfer set, and directions for use.

Composition:
Factor VIII, von Willebrand Factor, Arginine, Albumin
and Histidine.
Contains no preservatives.
Administer within three hours of reconstitution.
Discard unused contents.

GRIFOLS

Warning:
This product is prepared from large pools of
human plasma. Human blood and its components
may transmit infectious agents. See package
insert, WARNINGS AND PRECAUTIONS.

Instructions: The patient and physician should
discuss the risks and benefits of this product.
For information on dosage and directions for
administration, see enclosed package insert.

Storage: Store at temperatures not exceeding
25 °C (77 °F). Do not freeze.
Single dose container for intravenous
administration only.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, USA
U.S. License No. 1694

GRIFOLS

3070773

GTIN 00368516461822
LOT XXXXXXXXXX
EXP DDMMMYYYY
SN XXXXXXXXXX XXXXXX
IU FVIII/Vial XXXX
IU VWF: RCo/Vial XXXX

Carton Label 1000iu 10ml (Cartonlabel1000iu)

Carton Label 1000iu 10ml (Cartonlabel1000iu)

Principal Display Panel – 1500 IU Vial Label

NDC 68516-4608-2           1500 IU FVIII Range

Antihemophilic Factor/
von Willebrand Factor
Complex (Human)
Alphanate®   10 mL

Solvent Detergent / Heat Treated
Storage: Store at temperatures
not exceeding 25 °C (77 °F).
Rx only. Single dose container for
intravenous administration only. 

GRIFOLS  U.S. License No. 1694

Instructions: Reconstitute
with 10 mL of Sterile Water
for Injection, USP. Administer
promptly after reconstitution
and do not refrigerate. Discard
unused contents. For information
on dosage and directions for
administration, see accompanying
pamphlet. Contains no
preservatives. The patient and
physician should discuss the risks
and benefits of this product.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, U.S.A.

Lot

EXP

IU FVIII/Vial

IU VWF:RCo/Vial           3063706

Lot

IU FVIII/Vial

IU VWF:RCo/Vial

Alphanate®10 mL  NDC 68516-4608-2

Vial Label 1500iu 10ml (1500iulabel)

Vial Label 1500iu 10ml (1500iulabel)

Principal Display Panel – 1500 IU Carton Label

NDC 68516-4619-2          1500 IU FVIII Range

Antihemophilic Factor/von Willebrand
Factor Complex (Human)
Alphanate®

Solvent Detergent / Heat Treated

Rx only
For Intravenous Administration                 10 mL

GRIFOLS

Contents:
One vial Antihemophilic Factor/von Willebrand
Factor Complex (Human), Alphanate®, one vial
10 mL Sterile Water for Injection, USP, one
Mix2Vial® filter transfer set, and directions for use.

Composition:
Factor VIII, von Willebrand Factor, Arginine, Albumin
and Histidine.
Contains no preservatives.
Administer within three hours of reconstitution.
Discard unused contents.

GRIFOLS

Warning:
This product is prepared from large pools of
human plasma. Human blood and its components
may transmit infectious agents. See package
insert, WARNINGS AND PRECAUTIONS.

Instructions: The patient and physician should
discuss the risks and benefits of this product.
For information on dosage and directions for
administration, see enclosed package insert.

Storage: Store at temperatures not exceeding
25 °C (77 °F). Do not freeze.
Single dose container for intravenous
administration only.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, USA
U.S. License No. 1694

GRIFOLS

3070774

GTIN 00368516461921
LOT XXXXXXXXXX
EXP DDMMMYYYY
SN XXXXXXXXXX XXXXXX
IU FVIII/Vial XXXX
IU VWF: RCo/Vial XXXX

Carton Label 1500iu 10ml (Cartonlabel1500iu)

Carton Label 1500iu 10ml (Cartonlabel1500iu)

Principal Display Panel – 2000 IU Vial Label

NDC 68516-4610-2       2000 IU FVIII Range

Antihemophilic Factor/
von Willebrand Factor
Complex (Human)
Alphanate®       10 mL

Solvent Detergent / Heat Treated
Storage: Store at temperatures
not exceeding 25 °C (77 °F).
Rx only. Single dose container for
intravenous administration only. 

GRIFOLS  U.S. License No. 1694

Instructions: Reconstitute
with 10 mL of Sterile Water
for Injection, USP. Administer
promptly after reconstitution
and do not refrigerate. Discard
unused contents. For information
on dosage and directions for
administration, see accompanying
pamphlet. Contains no
preservatives. The patient and
physician should discuss the risks
and benefits of this product.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, U.S.A.

Lot

EXP

IU FVIII/Vial

IU VWF:RCo/Vial           3063704

Lot
10
IU FVIII/Vial

IU VWF:RCo/Vial

Alphanate®10 mL  NDC 68516-4608-2

Vial Label 2000iu 10ml (2000iulabel)

Vial Label 2000iu 10ml (2000iulabel)

Principal Display Panel – 2000 IU Carton Label

NDC 68516-4620-2          2000 IU FVIII Range

Antihemophilic Factor/von Willebrand
Factor Complex (Human)
Alphanate®

Solvent Detergent / Heat Treated

Rx only
For Intravenous Administration                 10 mL

GRIFOLS

Contents:
One vial Antihemophilic Factor/von Willebrand
Factor Complex (Human), Alphanate®, one vial
10 mL Sterile Water for Injection, USP, one
Mix2Vial® filter transfer set, and directions for use.

Composition:
Factor VIII, von Willebrand Factor, Arginine, Albumin
and Histidine.
Contains no preservatives.
Administer within three hours of reconstitution.
Discard unused contents.

GRIFOLS

Warning:
This product is prepared from large pools of
human plasma. Human blood and its components
may transmit infectious agents. See package
insert, WARNINGS AND PRECAUTIONS.

Instructions: The patient and physician should
discuss the risks and benefits of this product.
For information on dosage and directions for
administration, see enclosed package insert.

Storage: Store at temperatures not exceeding
25 °C (77 °F). Do not freeze.
Single dose container for intravenous
administration only.

Grifols Biologicals LLC
5555 Valley Boulevard
Los Angeles, CA 90032, USA
U.S. License No. 1694

GRIFOLS

3070775

GTIN 00368516462027
LOT XXXXXXXXXX
EXP DDMMMYYYY
SN XXXXXXXXXX XXXXXX
IU FVIII/Vial XXXX
IU VWF: RCo/Vial XXXX

Carton Label 2000 Iu 10ml (Cartonlabel2000iu)

Carton Label 2000 Iu 10ml (Cartonlabel2000iu)

* Please review the disclaimer below.